Skip to main content

Jim Cramer: Bristol-Myers Needs to Slim Down

Bristol-Myers Squibb needs to reorganize itself in what is now a challenging environment, says Jim Cramer.
  • Author:
  • Publish date:

Bristol-Myers Squibb (BMY) - Get Free Report is being viewed as a pharmaceutical company again,  TheStreet's Jim Cramer said -- not a rapidly growing biotech. That means the company needs to restructure itself, he commented.